Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2018 financial results and business highlights.
| What: | Vericel Corporation Fourth-Quarter 2018 Earnings Call | |
| When: | Tuesday, February 26, 2019 at 8:30am (EDT) | |
| Where: | ||
| How: | The conference call will be available live in the Investors section of the Vericel website at . Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2018 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at until February 26, 2020. A replay of the call will also be available until 11:15am (EDT) on March 3, 2019 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 3485006.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at .
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2019 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
(office)
(mobile)
Karen Chase
Russo Partners LLC
(office)
(mobile)
Investor Contacts:
Chad Rubin
Solebury Trout
+1 (646) 378-2947
Lee Stern
Solebury Trout
+1 (646) 378-2922
